BR112018004618A2 - ciano tienotriazoldiazepinas e usos das mesmas - Google Patents

ciano tienotriazoldiazepinas e usos das mesmas

Info

Publication number
BR112018004618A2
BR112018004618A2 BR112018004618-3A BR112018004618A BR112018004618A2 BR 112018004618 A2 BR112018004618 A2 BR 112018004618A2 BR 112018004618 A BR112018004618 A BR 112018004618A BR 112018004618 A2 BR112018004618 A2 BR 112018004618A2
Authority
BR
Brazil
Prior art keywords
diseases
compounds
bromodomain
proteins
pharmaceutical compositions
Prior art date
Application number
BR112018004618-3A
Other languages
English (en)
Portuguese (pt)
Inventor
E. Bradner James
Qi Jun
Tanaka Minoru
Buckley Dennis
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Publication of BR112018004618A2 publication Critical patent/BR112018004618A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112018004618-3A 2015-09-11 2016-09-09 ciano tienotriazoldiazepinas e usos das mesmas BR112018004618A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217521P 2015-09-11 2015-09-11
US62/217,521 2015-09-11
PCT/US2016/051107 WO2017044849A1 (en) 2015-09-11 2016-09-09 Cyano thienotriazolodiazepines and uses thereof

Publications (1)

Publication Number Publication Date
BR112018004618A2 true BR112018004618A2 (pt) 2018-09-25

Family

ID=58240288

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018004618-3A BR112018004618A2 (pt) 2015-09-11 2016-09-09 ciano tienotriazoldiazepinas e usos das mesmas

Country Status (20)

Country Link
US (1) US11306105B2 (enExample)
EP (1) EP3347021A4 (enExample)
JP (1) JP2018526421A (enExample)
KR (1) KR20180049058A (enExample)
CN (1) CN108472300A (enExample)
AU (1) AU2016319116B2 (enExample)
BR (1) BR112018004618A2 (enExample)
CA (1) CA2996974A1 (enExample)
CL (2) CL2018000621A1 (enExample)
CO (1) CO2018002483A2 (enExample)
CR (1) CR20180200A (enExample)
HK (1) HK1256417A1 (enExample)
IL (1) IL257594A (enExample)
MX (1) MX2018003031A (enExample)
PE (1) PE20181287A1 (enExample)
PH (1) PH12018550027A1 (enExample)
RU (1) RU2750164C2 (enExample)
SG (1) SG10202007090UA (enExample)
WO (1) WO2017044849A1 (enExample)
ZA (1) ZA201801548B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
CA2996977A1 (en) * 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
EP3686204B1 (en) * 2017-09-22 2025-11-05 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Thienodiazepine derivatives and application thereof
CN108084193A (zh) * 2017-12-19 2018-05-29 郭守东 一种brd4蛋白抑制剂
WO2020055976A1 (en) * 2018-09-11 2020-03-19 Genentech, Inc. Tert-butyl (s)-2-(4-(phenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain brd4 inhibitors for treating cancer
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
EP3917529A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
WO2022221786A2 (en) * 2022-06-22 2022-10-20 Plexium, Inc. Compounds and pharmaceutical compositions that modulate brd4

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3709898A (en) 1971-02-09 1973-01-09 Upjohn Co Process for the production of triazolobenzodiazepines and intermediates
US3681343A (en) 1971-05-11 1972-08-01 Upjohn Co 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
US3812259A (en) 1971-08-09 1974-05-21 Upjohn Co Animal feed and process
CH622019A5 (en) 1975-10-23 1981-03-13 Upjohn Co Process for the preparation of aminotriazolobenzodiazepines
FR2329668A1 (fr) 1975-10-27 1977-05-27 Upjohn Co Procede de preparation d'aminotriazolobenzodiazepines
EP0087850A1 (en) 1982-01-04 1983-09-07 The Upjohn Company Benzodiazepines for anti-hypertensive use
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
DE3778559D1 (de) 1986-01-21 1992-06-04 Boehringer Ingelheim Kg Thieno-1,4-diazepine.
ZA87377B (en) * 1986-01-21 1988-09-28 Boehringer Ingelheim Int New thieno-1,4-diazepine
DE3724164A1 (de) 1986-07-25 1988-01-28 Boehringer Ingelheim Kg Neue 1,4-benzodiazepine, ihre herstellung und verwendung
WO1988009333A1 (fr) 1987-05-28 1988-12-01 Yoshitomi Pharmaceutical Industries, Ltd. Compose a base de thieno(triazolo)diazepine et applications medicales de ce compose
JPH0676326B2 (ja) 1988-05-24 1994-09-28 吉富製薬株式会社 循環器系疾患治療薬
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) * 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
CA2020806A1 (en) 1989-07-12 1991-01-13 Karl-Heinz Weber Thienodiazepine derivatives
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
JP2959591B2 (ja) * 1990-05-23 1999-10-06 吉富製薬株式会社 チエノトリアゾロジアゼピン化合物
DE4107521A1 (de) * 1991-03-08 1992-09-10 Boehringer Ingelheim Kg Neue acylaminosubstituierte hetrazepine
JP3239364B2 (ja) 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
EP0661284A1 (en) 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
CA2159344A1 (en) * 1993-03-30 1994-10-13 Minoru Moriwaki Cell adhesion inhibitor and thienotriazolodiazepine compound
JP3001979U (ja) 1994-03-14 1994-09-06 有限会社マルセ木工 竿掛け具
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
ATE203026T1 (de) 1995-01-06 2001-07-15 Hoffmann La Roche Hydroxymethyl-imidazodiazepine und deren ester
ATE230600T1 (de) 1995-09-09 2003-01-15 Hoffmann La Roche Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
IL127516A0 (en) 1996-06-12 1999-10-28 Japan Tobacco Inc A cytokine production inhibitor
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
WO1998011111A1 (en) 1996-09-13 1998-03-19 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and medicinal uses thereof
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JPH11228576A (ja) 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US7589167B2 (en) 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
CA2412776C (en) 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
US6552037B2 (en) 2000-06-30 2003-04-22 Neurogen Corporation 2-Substituted imidazo[1,2-A]pyridine derivatives
US20060142257A1 (en) 2001-01-19 2006-06-29 Eberhard Nieschlag Male contraceptive formulation comprising norethisterone
US6979682B2 (en) 2001-02-23 2005-12-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
CA2458699C (en) 2001-09-04 2010-10-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20030216758A1 (en) 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP3096299U (ja) 2003-02-20 2003-09-12 宇輪工業股▲ふん▼有限公司 足踏み式健康器
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DK1599478T3 (da) 2003-02-26 2007-09-17 Boehringer Ingelheim Pharma Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2005002526A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
CA2538413A1 (en) 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
WO2006021548A1 (de) 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US8044042B2 (en) 2005-05-30 2011-10-25 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and medicinal use thereof
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX286273B (es) 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
CA2617589A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EP1962830B1 (en) 2005-12-23 2013-03-27 GlaxoSmithKline LLC Azaindole inhibitors of aurora kinases
KR101062583B1 (ko) 2006-01-17 2011-09-06 에프. 호프만-라 로슈 아게 Ｇａｂａ 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-ａ]피리딘
TW200804389A (en) 2006-02-14 2008-01-16 Vertex Pharma Dihydrodiazepines useful as inhibitors of protein kinases
ES2351367T3 (es) 2006-02-14 2011-02-03 Vertex Pharmaceuticals Incorporated Dihidrodiazepinas útiles como inhibidores de proteína quinasas.
US20070218135A1 (en) 2006-03-14 2007-09-20 Glenmark Pharmaceuticals Limited Sustained release matrix pharmaceutical composition
WO2007131005A2 (en) 2006-05-03 2007-11-15 Novartis Ag Use of organic compounds
JP2009537500A (ja) 2006-05-19 2009-10-29 アストラゼネカ アクチボラグ 増殖抑制剤としてのジヒドロプテリジン化合物
WO2008009909A1 (en) 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
KR101504669B1 (ko) 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
EA200900593A1 (ru) 2006-10-25 2010-06-30 Хрома Терапьютикс Лтд. Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
ES2805286T3 (es) 2006-12-26 2021-02-11 Lantheus Medical Imaging Inc Ligandos para la formación de imágenes de la inervación cardíaca
CA2680757A1 (en) 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
WO2008137081A1 (en) 2007-05-02 2008-11-13 The Trustees Of Columbia University In The City Of New York Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
EP2564850B1 (en) 2007-09-25 2014-08-13 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CA2700979C (en) 2007-09-28 2017-06-20 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009080638A2 (en) 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
ES2424982T3 (es) 2008-03-10 2013-10-10 Janssen Pharmaceutica, N.V. 4-Aril-2-anilino-pirimidinas como inhibidores de cinasas PLK
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
FR2928923B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
WO2010015340A1 (en) 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
WO2010032195A1 (en) 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
CN102292341B (zh) 2008-10-30 2014-09-10 环行医学有限责任公司 对apo a有活性的噻吩并三唑并二氮杂*衍生物
PL2356123T3 (pl) 2008-11-13 2013-03-29 Hoffmann La Roche Spiro-5,6-dihudro-4h-2,3,5,10b- tetraazabenzo[e]azuleny
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
BRPI1007358A2 (pt) 2009-01-23 2018-03-06 Takeda Pharmaceutical Company Limited inibidores de poli (adp-ribose) polimerase (parp)
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
EP2480550B1 (en) 2009-09-25 2016-02-10 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
RS53179B (sr) 2009-11-05 2014-06-30 Glaxosmithkline Llc Benzodiazepinski inhibitor bromodomena
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
ES2654423T3 (es) 2009-11-05 2018-02-13 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiacepina
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
JP5844358B2 (ja) * 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
US20120014979A1 (en) 2010-07-16 2012-01-19 Alexander Dent Use of bcl6 inhibitors for treating autoimmune diseases
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2677865A4 (en) 2011-02-23 2015-04-22 Icahn School Med Mount Sinai BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
US9127074B2 (en) 2011-03-07 2015-09-08 Fondazione Telethon TFEB variants and uses thereof
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013123521A1 (en) 2012-02-17 2013-08-22 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients
US20150133434A1 (en) 2012-03-28 2015-05-14 The J. David Gladstone Institutes Compositions and Methods for Reactivating Latent Immunodeficiency Virus
CA2878996C (en) 2012-08-08 2021-09-14 Novomatic Ag Method of and system for tracking gaming activity
HK1211209A1 (en) 2012-09-28 2016-05-20 Oncoethix Gmbh Pharmaceutical formulation containing thienotriazolodiazepine compounds
US9567301B2 (en) 2012-11-02 2017-02-14 Dana-Farber Cancer Institute, Inc. Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors
US20160193206A1 (en) 2012-12-20 2016-07-07 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydropyridopyrazinones
AU2014249034A1 (en) 2013-03-11 2015-09-24 Abbvie Inc. Fused tetracyclic bromodomain inhibitors
US20140254659A1 (en) 2013-03-11 2014-09-11 Mediatek Inc. Video coding method using at least evaluated visual quality and related video coding apparatus
CN108440528A (zh) 2013-03-12 2018-08-24 艾伯维公司 四环布罗莫结构域抑制剂
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
WO2015081284A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
AU2014361381A1 (en) 2013-12-10 2016-06-16 Abbvie Inc. Bromodomain inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
CN105940005A (zh) 2014-01-31 2016-09-14 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
US20160347750A1 (en) 2014-01-31 2016-12-01 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3110819A4 (en) 2014-02-26 2017-08-02 Kyorin Pharmaceutical Co., Ltd. Heterocyclic compounds
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA2955074A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
WO2016090219A1 (en) 2014-12-05 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bromodomain inhibitor as adjuvant in cancer immunotherapy
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
EP3347356B1 (en) 2015-09-09 2021-03-24 Jubilant Biosys Limited Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors
EA033978B1 (ru) 2015-09-11 2019-12-16 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
CA2996977A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
EP3888658B1 (en) 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
AU2016361428A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Triazole ACC inhibitors and uses thereof
SI3379933T1 (sl) 2015-11-25 2023-07-31 Gilead Apollo, Llc Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
MX2018006288A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc tipo ester y usos de los mismos.
HUE064791T2 (hu) 2015-11-25 2024-04-28 Visterra Inc APRIL ellenes antitest molekulák és alkalmazásaik
US20170166582A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CN108290858B (zh) 2015-12-01 2021-07-06 日本农药株式会社 3h-吡咯并吡啶化合物或其n-氧化物、或它们的盐类及含有该化合物的农业园艺用杀虫剂及其使用方法
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
GB201608797D0 (en) 2016-05-19 2016-07-06 Ucb Biopharma Sprl Therapeutic use
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase

Also Published As

Publication number Publication date
US20200199150A1 (en) 2020-06-25
CL2018000621A1 (es) 2018-07-20
SG10202007090UA (en) 2020-08-28
US11306105B2 (en) 2022-04-19
IL257594A (en) 2018-04-30
AU2016319116A1 (en) 2018-03-29
US20210206779A9 (en) 2021-07-08
RU2018112961A3 (enExample) 2019-12-09
KR20180049058A (ko) 2018-05-10
EP3347021A4 (en) 2019-07-24
PE20181287A1 (es) 2018-08-07
HK1256417A1 (zh) 2019-09-20
AU2016319116B2 (en) 2020-10-01
EP3347021A1 (en) 2018-07-18
RU2750164C2 (ru) 2021-06-22
WO2017044849A1 (en) 2017-03-16
CL2020002530A1 (es) 2021-01-29
CR20180200A (es) 2018-05-31
CA2996974A1 (en) 2017-03-16
PH12018550027A1 (en) 2018-09-24
MX2018003031A (es) 2018-08-01
WO2017044849A8 (en) 2017-09-28
RU2018112961A (ru) 2019-10-11
JP2018526421A (ja) 2018-09-13
ZA201801548B (en) 2021-07-28
CO2018002483A2 (es) 2018-07-19
CN108472300A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
BR112018004618A2 (pt) ciano tienotriazoldiazepinas e usos das mesmas
BR112018004617A2 (pt) acetamida tienotriazoldiazepinas e usos das mesmas
BR112017002369A2 (pt) derivados de diazepana e usos dos mesmos
BR112016017045A2 (pt) Derivados de diazepano e usos dos mesmos
BR112017002190A2 (pt) derivados de di-hidropteridinona e usos dos mesmos
MX2016009975A (es) Derivados de dihidropteridinona y sus usos.
BR112018009798A2 (pt) inibidores de bromodomínio bivalentes e usos dos mesmos
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
BR112019002646A2 (pt) composições de poxvírus quimérico e usos das mesmas
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
BR112018015419A2 (pt) degradantes seletivos de receptor de estrogênio e os usos dos mesmos
BR112016024626A8 (pt) compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
HUE055658T2 (hu) PTHRP analógokat tartalmazó készítmények, ezeket tartalmazó transzdermális tapaszok és ezek alkalmazása
DK3294323T3 (da) Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet
BR112017002761A2 (pt) composições anti-metanogênicas e usos das mesmas
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112015029953A2 (pt) anticorpos anti-tweakr e seus usos
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
BR112016022214A2 (pt) rnase para uso no tratamento ou prevenção de infecções virais
BR112012030816A2 (pt) agentes antiinflamatórios

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2687 DE 05-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.